|
Acurx Pharmaceuticals, Inc., a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections, announced that the Japan Patent Office and the Mexico Patent Office, respectively, have each granted a new patent which covers Acurx's DNA Polymerase IIIC inhibitors including compositions-of-matter, methods of use, and pharmaceutical compositions, which further strengthen Acurx's intellectual property portfolio and represents the most recent addition to the company's expanding series of granted patents in the US and abroad. To date, Acurx has secured six US patents and an additional ten patents internationally, including Australia, Canada, Europe, Israel, India, Japan, Korea, and Mexico, all of which protect key aspects of the company's ibezapolstat and the ACX-375C programme targeting DNA Polymerase IIIC. Additional country-level patent applications remain under review.
David P. Luci, president and chief executive officer of Acurx, stated: "Achieving these additional new patents extend our patent estate protection as we further develop ibezapolstat and our innovative, AI-supported drug discovery platform."
Robert J. DeLuccia, executive chairman of Acurx, stated, "We believe Acurx's ibezapolstat and preclinical pipeline of systemically absorbed antibiotics has the potential to create a transformational shift in the treatment paradigm of certain serious and potentially life-threatening infections without promoting antibiotic-induced gut dysbiosis. These infections include C. difficile, acute bacterial skin and skin-structure infections (ABSSSI, including MRSA), Community-acquired bacterial pneumonia (CABP), hospital and/or ventilator-associated bacterial pneumonia (HABP/VABP), bacteremia with or without sepsis and/or infectious endocarditis, bone/joint infections, prosthetic joint infections and inhalational anthrax, caused by B. anthracis, a Bioterrorism Category A Threat-Level pathogen."
Acurx Pharmaceuticals is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that blocks the active site of the Gram+ specific bacterial enzyme DNA polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its R&D pipeline includes antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile, methicillin- resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE), drug- resistant Streptococcus pneumoniae (DRSP) and B. anthracis (anthrax; a Bioterrorism Category A Threat-Level pathogen).
|